Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05611671




Registration number
NCT05611671
Ethics application status
Date submitted
31/10/2022
Date registered
10/11/2022
Date last updated
28/06/2024

Titles & IDs
Public title
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
Scientific title
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-2)
Secondary ID [1] 0 0
MORF-057-202
Universal Trial Number (UTN)
Trial acronym
EMERALD-2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Inflammatory Bowel Diseases 0 0
Colitis, Ulcerative 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - MORF-057
Treatment: Drugs - Placebo

Experimental: Group 1 - MORF-057 Dosing Regimen One for Induction and Maintenance Periods

Experimental: Group 2 - MORF-057 Dosing Regimen Two for Induction and Maintenance Periods

Experimental: Group 3 - MORF-057 Dosing Regimen Three for Induction and Maintenance Periods

Placebo comparator: Group 4 - Matching Placebo Dosing Regimen for Induction and MORF-057 Dosing Regimen Four for Maintenance


Treatment: Drugs: MORF-057
MORF-057 is a small molecule that is designed to selectively inhibit integrin a4ß7 and is administered orally.

Treatment: Drugs: Placebo
Matching placebo (identical appearance to MORF-057) administered orally.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of participants in clinical remission at Week 12 as determined using the Modified Mayo Clinic Score (mMCS).
Timepoint [1] 0 0
From baseline to 12 weeks
Secondary outcome [1] 0 0
Change from baseline to Week 12 in clinical response in the Modified Mayo Clinic Score (mMCS)
Timepoint [1] 0 0
From baseline to 12 weeks

Eligibility
Key inclusion criteria
* Has signs/symptoms of moderate to severe UC for at least 3 months prior to Screening
* Has evidence of UC extending at least 15 cm from the anal verge
* Demonstrated an inadequate response, loss of response, or intolerance to at least one of the following treatments: Oral aminosalicylates (e.g., mesalamine, sulfasalazine, olsalazine, or balsalazide), corticosteroids, immunosuppressants (e.g., azathioprine, 6-mercaptopurine, or methotrexate), advanced therapies for UC (e.g., biologic agents, Janus kinase [JAK] antagonists, or sphingosine-1-phosphate [S1P] receptor agonists)
* Subject has no prior exposure to approved or investigational anti-integrin therapies
* Agrees to abide by the study guidelines and requirements
* Capable of giving signed informed consent
Minimum age
18 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, or Crohn's disease or has clinical findings suggestive of Crohn's disease
* Has positive findings on a subjective neurological screening questionnaire
* Has a concurrent, clinically significant, serious, unstable comorbidity
* Previous treatment with vedolizumab or other licensed or investigational integrin inhibitors
* Participation in any other interventional study or received any investigational therapy within 30 days
* Previous exposure to MORF-057 and/or a known hypersensitivity to drugs with a similar mechanism to MORF-057
* Unable to attend study visits or comply with study procedures

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
31/10/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/07/2025
Actual
Sample size
Target
280
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Clinical Study Site - Blacktown
Recruitment hospital [2] 0 0
Clinical Study Site - Concord
Recruitment hospital [3] 0 0
Clinical Study Site - Brisbane
Recruitment hospital [4] 0 0
Clinical Study Site - Parkville
Recruitment hospital [5] 0 0
Clinical Study Site - Murdoch
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
2139 - Concord
Recruitment postcode(s) [3] 0 0
4029 - Brisbane
Recruitment postcode(s) [4] 0 0
4101 - Brisbane
Recruitment postcode(s) [5] 0 0
3050 - Parkville
Recruitment postcode(s) [6] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Kansas
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
New Jersey
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
South Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
Austria
State/province [12] 0 0
Linz
Country [13] 0 0
Austria
State/province [13] 0 0
Salzburg
Country [14] 0 0
Austria
State/province [14] 0 0
Vienna
Country [15] 0 0
Bulgaria
State/province [15] 0 0
Ruse
Country [16] 0 0
Bulgaria
State/province [16] 0 0
Sofia
Country [17] 0 0
Czechia
State/province [17] 0 0
Olomouc
Country [18] 0 0
Czechia
State/province [18] 0 0
Prague
Country [19] 0 0
Czechia
State/province [19] 0 0
Slaný
Country [20] 0 0
Estonia
State/province [20] 0 0
Pärnu
Country [21] 0 0
Estonia
State/province [21] 0 0
Tallinn
Country [22] 0 0
Estonia
State/province [22] 0 0
Tartu
Country [23] 0 0
France
State/province [23] 0 0
Lille
Country [24] 0 0
France
State/province [24] 0 0
Nice
Country [25] 0 0
France
State/province [25] 0 0
Pierre-Bénite
Country [26] 0 0
France
State/province [26] 0 0
Saint-Priest-en-Jarez
Country [27] 0 0
France
State/province [27] 0 0
Vandœuvre-lès-Nancy
Country [28] 0 0
Georgia
State/province [28] 0 0
Tbilisi
Country [29] 0 0
Germany
State/province [29] 0 0
Baden-Wuerttemberg
Country [30] 0 0
Germany
State/province [30] 0 0
Bavaria
Country [31] 0 0
Germany
State/province [31] 0 0
North Rhine-Westphalia
Country [32] 0 0
Germany
State/province [32] 0 0
Saxony
Country [33] 0 0
Germany
State/province [33] 0 0
Schleswig-Holstein
Country [34] 0 0
Germany
State/province [34] 0 0
Berlin
Country [35] 0 0
Hungary
State/province [35] 0 0
Budapest
Country [36] 0 0
Hungary
State/province [36] 0 0
Gyongyos
Country [37] 0 0
Hungary
State/province [37] 0 0
Szekesfehervar
Country [38] 0 0
Hungary
State/province [38] 0 0
Vac
Country [39] 0 0
India
State/province [39] 0 0
Delhi
Country [40] 0 0
India
State/province [40] 0 0
Gujarat
Country [41] 0 0
India
State/province [41] 0 0
Haryana
Country [42] 0 0
India
State/province [42] 0 0
Kerala
Country [43] 0 0
India
State/province [43] 0 0
Punjab
Country [44] 0 0
India
State/province [44] 0 0
Rajasthan
Country [45] 0 0
India
State/province [45] 0 0
Telangana
Country [46] 0 0
India
State/province [46] 0 0
Uttar Pradesh
Country [47] 0 0
Israel
State/province [47] 0 0
Be'er Sheva
Country [48] 0 0
Israel
State/province [48] 0 0
Jerusalem
Country [49] 0 0
Israel
State/province [49] 0 0
Nahariya
Country [50] 0 0
Israel
State/province [50] 0 0
Re?ovot
Country [51] 0 0
Italy
State/province [51] 0 0
Florence
Country [52] 0 0
Italy
State/province [52] 0 0
Milan
Country [53] 0 0
Italy
State/province [53] 0 0
Padova
Country [54] 0 0
Italy
State/province [54] 0 0
San Giovanni Rotondo
Country [55] 0 0
Italy
State/province [55] 0 0
Turin
Country [56] 0 0
Korea, Republic of
State/province [56] 0 0
Busan
Country [57] 0 0
Korea, Republic of
State/province [57] 0 0
Daegu
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Gyeonggi-do
Country [59] 0 0
Korea, Republic of
State/province [59] 0 0
Seongnam-si
Country [60] 0 0
Korea, Republic of
State/province [60] 0 0
Seoul
Country [61] 0 0
Latvia
State/province [61] 0 0
Liepaja
Country [62] 0 0
Latvia
State/province [62] 0 0
Riga
Country [63] 0 0
Lithuania
State/province [63] 0 0
Panevezys
Country [64] 0 0
Lithuania
State/province [64] 0 0
Vilnius
Country [65] 0 0
Poland
State/province [65] 0 0
Bydgoszcz
Country [66] 0 0
Poland
State/province [66] 0 0
Elblag
Country [67] 0 0
Poland
State/province [67] 0 0
Kraków
Country [68] 0 0
Poland
State/province [68] 0 0
Lublin
Country [69] 0 0
Poland
State/province [69] 0 0
Opole
Country [70] 0 0
Poland
State/province [70] 0 0
Poznan
Country [71] 0 0
Poland
State/province [71] 0 0
Sopot
Country [72] 0 0
Poland
State/province [72] 0 0
Staszów
Country [73] 0 0
Poland
State/province [73] 0 0
Szczecin
Country [74] 0 0
Poland
State/province [74] 0 0
Tychy
Country [75] 0 0
Poland
State/province [75] 0 0
Wadowice
Country [76] 0 0
Poland
State/province [76] 0 0
Warsaw
Country [77] 0 0
Poland
State/province [77] 0 0
Wroclaw
Country [78] 0 0
Poland
State/province [78] 0 0
Zamosc
Country [79] 0 0
Poland
State/province [79] 0 0
Lódz
Country [80] 0 0
Romania
State/province [80] 0 0
Bucharest
Country [81] 0 0
Romania
State/province [81] 0 0
Iasi
Country [82] 0 0
Serbia
State/province [82] 0 0
Belgrade
Country [83] 0 0
Serbia
State/province [83] 0 0
Pancevo
Country [84] 0 0
Serbia
State/province [84] 0 0
Zrenjanin
Country [85] 0 0
Slovakia
State/province [85] 0 0
Bratislava
Country [86] 0 0
Slovakia
State/province [86] 0 0
Košice
Country [87] 0 0
Slovakia
State/province [87] 0 0
Prešov
Country [88] 0 0
Taiwan
State/province [88] 0 0
Changhua City
Country [89] 0 0
Taiwan
State/province [89] 0 0
Chiayi City
Country [90] 0 0
Taiwan
State/province [90] 0 0
New Taipei City
Country [91] 0 0
Taiwan
State/province [91] 0 0
Taichung
Country [92] 0 0
Taiwan
State/province [92] 0 0
Taipei

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Morphic Therapeutic, Inc
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Morphic Therapeutic, Inc
Address 0 0
Country 0 0
Phone 0 0
781-996-0955
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT05611671